Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| Transactions in connection with share buy-back program |
| 4 Jul 2022 |
| Major Shareholder Announcement | 1 Jul 2022 |
| Transactions in connection with share buy-back program | 27 Jun 2022 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 23 Jun 2022 |